Related Articles
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
Transformation from adenocarcinoma to squamous cell carcinoma associated with long‑term administration of EGFR‑TKIs
Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report
Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3